How has been the historical performance of Piramal Pharma?

Answer:The historical performance of Piramal Pharma shows a fluctuating trend in key financial metrics over the past four years.

Breakdown:
Piramal Pharma's net sales have consistently increased from INR 6,559.10 crore in March 2022 to INR 9,151.18 crore in March 2025. Total operating income followed a similar upward trajectory, reaching INR 9,151.18 crore in March 2025, up from INR 6,559.10 crore in March 2022. However, total expenditure also rose significantly, from INR 5,609.44 crore in March 2022 to INR 7,706.35 crore in March 2025. Operating profit (PBDIT) improved from INR 1,225.46 crore in March 2022 to INR 1,579.64 crore in March 2025, indicating a recovery in profitability, despite a dip in profit before tax in March 2023 to -INR 174.48 crore. The profit after tax showed a notable recovery, moving from a loss of INR 240.79 crore in March 2023 to a profit of INR 18.20 crore in March 2025. The company's total assets increased from INR 12,499.77 crore in March 2022 to INR 15,284.46 crore in March 2025, while total liabilities also rose from INR 12,499.77 crore to INR 15,284.46 crore in the same period. Cash flow from operating activities peaked at INR 892 crore in March 2025, although the net cash outflow was recorded at -INR 36 crore. Overall, while Piramal Pharma faced challenges, particularly in 2023, the company has shown signs of recovery and growth in its financial performance by March 2025.